| Product Candidate | Proprietary Platform | Indication | Development Stage | Years IP | Prevalence (Millions) | |||
|---|---|---|---|---|---|---|---|---|
| Discovery | Pre‑Clinical | Phase I | Phase II/III | |||||
| ND10Oral | 7-MX | UV-B Cataract Prevention |
|
20 | 3+ (US) / 15+ (GL) | |||
| ND10Eye Drop | 7-MX | Dry Eye Disease |
|
20 | 35+ (US) / 700+ (GL) | |||
| ND10ER, Oral | 7-MX | High Myopia Control |
|
20 | 1.2+ (US) / 35+ (GL) | |||
| rHCT3-1Film/Implant | rHCT3 | Corneal Blindness |
|
20 | 2+ (US) / 12.7 (GL) | |||
| rHCT3-2Eye Drops | rHCT3 | Keratoconus |
|
20 | 0.5+ (US) / 9.6 (GL) | |||
| XP37Back Eye Drop | XP | Neo Vascular AMD |
|
20 | 1.75 (US) / 200 (GL) | |||
| XP37Back Eye Drop | XP | Pterygium |
|
20 | 10 (US) / 200 (GL) | |||